Last Modified: July 6, 2003
Conference Dates: October 8-11, 2003
Conference Location: New York, NY
Sponsoring Group: New York University
Conference Web Page URL: www.imedex.com/announcements/platinum03.html
Topics Covered: This symposium combines the latest information on both the clinical and mechanistic aspects of the use of platinum-based anticancer agents. The contributions and current status of cisplatin and carboplatin in cancer therapy will be reviewed. Clinical data on more recently approved and emerging drugs especially oxaliplatin will be presented. The clinical status of other drug candidates as well as drug formulations will be reviewed.
On the mechanistic front, the sessions will summarize recent advances in analysis of gene expression of platinum toxicity from human tumor cell lines. The consequences of platinum binding to target DNA will be explored in this context through discussion of the specifics of protein recognition and cellular repair pathways. Fundamental scientific approaches to developing novel targets for platinum-based drugs such as mitochondrial targets and novel DNA-binding modes such as telomerase, topoisomerase and antisense strategies will be described by experts in the field. This quadrennial conference on one of the most important classes of anti-cancer drugs in use today offers a unique opportunity to hear the latest advances from both basic scientists and clinicians. Moreover, the central role of platinum compounds in cancer therapy will be projected into state-of-the-art sessions covering gastrointestinal, genitourinary, gynecologic, and pulmonary cancers that should be of interest to scientists working in all oncologic specialties.
Conference Objectives: -Discuss the effect of platinum-compounds on DNA and other vital cellular components, Explain the mechanisms of delivery to and transport into the cells and the toxicity of platinum compounds, Describe the role of platinum compounds in the treatment of various types of cancer, Summarize the results of recent clinical trials and outline the future of platinum-based chemotherapy
Who Should Attend: This program is intended for specialists in biotechnology, drug development and clinical researchers with an interest in the development and use of platinum and other heavy metal compounds in the treatment of cancer. A basic familiarity with the cellular and molecular biology of normal and cancer cells and with the principles of drug development is required for successful participation in this program.
Registration Information: Register online at www.med.nyu.edu/cme or send registration form to Registration Office, NYU Post-Graduate Medical School P. O. Box 1855, Murray Hill Station, New York, NY 10016
Conference Fees: Physicians/Academia: $399 early (registered by July 25), $499 Regular (registered by Sept. 26), $599 Full (after Sept. 26 or on-site)
Continuing Education: Yes
Miscellany: This activity is co-sponsored by New York University, Post-Graduate Medical School and Imedex®, Inc. New York University, Post-Graduate Medical School and Imedex, Inc. are accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Imedex, Inc. designates this educational activity for a maximum of 25 category 1 credits toward the AMA Physician?s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
Aug 15, 2012 - For patients with non-small-cell lung cancer who undergo neoadjuvant platinum-based chemotherapy, tissue platinum concentrations correlate positively with improved outcome, according to a study published online Aug. 13 in the Journal of Clinical Oncology.